To measure changes in bone alkalinephosphatase (EC 3.1.3.1) activity in serum as a function of duration of pregnancy, we adapted our existing alkaline phosphatase (ALP) isoenzyme assay (which has been used to measure bone, hepatic, and intestinal ALP activities in serum, in the absence of placental ALP) to allow quantification of individual ALP isoenzyme activities inthe presence of placental ALP. The resulting CV for repeat measurements of bone ALP activity in artificial isoenzyme mixtures ranged from 23% for samples in which the bone isoenzyme represented 7% of total ALP activity to 11% for samples in which bone ALP accounted for 48% of total ALP activity. Values for repeat determinations of bone ALP activity in human serum samples (i.e., including samples obtained from pregnant women and from nonpregnant controls) varied by an average of 18%. We find, in initial applications of this method, that (a) the amount of bone ALP activity in serum is increased during pregnancy (P <.001), and remains increased at six weeks postpartum, in non-lactating women (P <.001), and (b) bone ALP activity at term was not significantly different in pregnant women with pre-eclampsia, diabetes, premature rupture of membranes, or premature labor, compared with normal pregnancies at term. Our data support the hypothesis that maternal bone formation may be increased during pregnancy.
depends upon a supply of dietary calcium sufficient to more than meet the fetal demand.
To test the hypothesis that maternal bone formation may be increased during pregnancy, and to quantify the increase, we measured alkaline phosphatase (ALP) skeletal isoenzyme activity in serum as an index of the rate of bone formation. We had three reasons for making this choice of analyte. First, previous studies had shown a close association between skeletal ALP isoenzyme activity in serum and the rate ofbone formation, both in vitro (6) and in vivo (7) (8) (9) .
Second, previous studies also indicated that the pregnancy-dependentincrease in total ALP activity in serum might reflect increases in both the placental (10, 11) and skeletal ALP isoenzymes (12, see reference 13 for a general review).
And finally, we had already established an assay that would allowus toquantifyindividual ALP isoenzyme activities in the circulating mixture of bone, hepatic,and intestinal ALPs of the non-pregnant subject (14) .
We had two objectives in the current studies: (a) to modify our existing ALP isoen.zyme assay so that we could accurately measure bone ALP activity in a fourcomponent isoen.zyme mixture (i.e., bone, hepatic, intestinal, and placental ALPs); and (b) to apply the modified assay to determine time-dependent changes in serum ALP isoenzyme activities during normal pregnancy, and to compare ALP isoenzyme distributions, at term, in normal and abnormal pregnancies.
Materials and Methods

Chemicals and Supplies
Purified human placental ALP, NaHCO3, Na2CO3, and pnitrophenyl phosphate were from Sigma Chemical Co., St. Louis, MO. Pooled human serum (mycoplasma-free) was from Flow Laboratories, McLean, VA. For colorirnetry of ALP activity we used an automated motorized micro-well plate reader (Dynatech, Richmond, VA; Model MR-600).
Description of the Study Population
We first studied 19 non-pregnant women, to evaluate the possible significance of circadianrhythms and fasting on ALP isoenzyme activities in serum. Serum samples were obtained from volunteers(a) at 1-mm intervals, (b) at different times of the day, (c) during fasting, and (d) after a meal. No variations were found. For our pregnancy study, we recruited 22 women, 26 (SD 3) years old, who had received prenatal care at the Loma Linda University Hospital. No distinctions were made with respect to previous pregnancies and (or) deliveries. After informed consent was obtained, blood specimens were taken at one or more of the following four times during pregnancy: 10-12 weeks (i.e., near the end of the first trimester), 18-20 weeks (near the midpoint of the second trimester), 32-34 weeks (near the end of the third trimester), and six weeks postpartum (non-lactating women). We originally intended to obtain longitudinal data, but had to revert to a crosssectional design because of (e.g.) poor compliance with our sampling schedule, change in subject's residence, etc. ) the results of our isoenzyme assays were normalized by including isoenzyme standards in each assay. Serum isoenzyme standards were used for bone ALP (i.e., serum from subjects with active Paget's disease, for whom we assume that total serum ALP activity = bone ALP activity >800 U/L) and hepatic ALP (i.e., serum from subjects with obstructive jaundice and cholestasis, for whom we assume that total serum ALP activity = hepatic ALP activity >500 U/L). Human intestinal ALP activity was extracted (and partly purified) from sections of duodenum, obtained at autopsy. A highly purified preparation of human placental ALP was obtained commercially.
For the current studies, we also adapted our assay to an automatic microtiter plate spectrophotometer/printer.
(The automated plate reader can measure and record the absorbancies of 96 separate samples in less than 2 mm.) To adapt the assay to this system, total reaction volumes were decreased from 1.5 mL to 0. aliquots were then transferred to a third microtiter plate, and 30-ML of carbonate buffer (pH 10.3) was added to each well for subsequent measurements of heat-resistant ALP activity.
(e) Finally, the test tubes were returned to the 53 #{176}C water bath for an additional 90 mm, then duplicate 25-4 aliquots were transferred to a fourth microtiter plate, and 30 4 of carbonate buffer (pH 10.3) was added to each well for subsequent measurements of heat-stable ALP activity.
At this point, the diluted serum samples were distributed over four microtiter plates such that duplicate aliquots of untreated sera were in one plate, sera with phenylalanine in the second plate, il-mm-heated sera in the third plate, and 101-mm-heated sera (i.e., 11 mm + 90 mm) in the fourth plate. The total volume in each well was 55 4. ALP activities were then determined by adding 245 4 of our standard ALP reaction mixture to each well. Controls without added enzyme were included on each plate to correct for nonspecific hydrolysis of p-nitrophenyl phosphate. As in previous studies (14) , isoenzyme standards (diluted in carbonate buffer, water, and heat-inactivated human serum, as appropriate) were also included on each plate, to correct for interassay variations.
The reactions were initiated by adding p-nitrophenyl phosphate (in the reaction mixture) and monitored by the time-dependent increase in absorbance at 404 nm (i.e., reflecting the production of the p-nitrophenolate anion in the alkaline assay environment), at ambient room temperature (22 #{176}C). The standard assay ran for 40 mm, but both shorter and longer incubations were used to measure high and low activities, respectively. As outlined in Results, ALP isoenzyme activities were then calculated by the simultaneous solution of four equations containing four unknowns. Isoenzyme activity factors (a, b, c, etc.) were determined from the isoenzyme standards in each assay (e.g., if 11 mm at 53 #{176}C decreased the activity of the bone ALP standard by 65%, the factor "e" would be equal to 0.35 for that assay).
All ALP activities are reported in U/L (of serum)-. microtiter plates, allowing space for controls and isoenzyme standards on each plate. Because the aliquots of the diluted sera could also be stored frozen (-20 #{176}C) in the microtiter plates without apparent loss of activity, multiple sets of plates could be included in an assay, so that 80 or 120 serum samples could be analyzed together.
Sample Storage and Stability
The serum samples used in these investigations were collected over a period of 15 months and stored at -20 #{176}C until the assays were performed. Because previous studies (14) had shown that the variation between ALP isoenzyme assays exceeded the variation within assays, we planned to assay the samples all together, or, at least, in three large groups (i.e., including preliminary samples from the nonpregnant, volunteer controls, time-dependent pregnancy samples, and term samples from women with different metabolic status, respectively). To ensure that ALP isoenzyme activities were not lost or altered during frozen storage, we removed aliquots from some samples (including both controls and pregnant subjects) before they were frozen, to allow a comparison of ALP isoenzyme activities before and after eight months of frozen storage.
Statistical Analyses
As mentioned, we were only able to obtain a complete series of samples (i.e., at 10-12, 18-20, and 32-34 weeks, and six weeks postpartum) from a total of four subjects. Therefore, we have treated the data as cross-sectional. For statistical comparisons we used analysis of variance and Student's two-tailed t-test (paired or unpaired, as appropriate) and linear regression analysis.
Results
ALP lsoenzyme Assay (a) Chemical and thermal stabilities of ALP isoenzymes.
ALP isoenzyme standards, diluted in appropriate mixtures of carbonate buffer (25 mmoltL, pH 8.0), water, and heatinactivated human serum, were used to determine the inhibitory actions of 10 mmollL i-phenylalanine and incubation at 53 #{176}C. (Heat-inactivated human serum was prepared by incubating serum at 53 #{176}C, until ALP activity could no longer be detected in a 25-4 aliquot.) As summarized in Table 1 , we found that both the intestinal and placental ALP isoenzymes were significantly inhibited by phenylalanine, all four isoenzymes were differentially inactivated by an il-mm incubation at 53 #{176}C, and only placental ALP activity was retained after a 101-mm incubation at 53 #{176}C. These data, which are consistent with previous reports (see reference 13 for a review), allowed us to define the four equations (i.e., for total ALP activity, phenylalanmneresistant ALP activity, heat-resistant ALP activity, and heat-stable ALP activity-see
Methods)
required to measure the four unknown ALP isoenzyme activities (i.e., bone, hepatic, intestinal, and placental).
(b) Design and characterization of the assay. The 101-mm incubation at 53 #{176}C allowed for quantification of placental ALP activity, so we defined heat-stable ALP activity as placental ALP. Serum samples that contained significant amounts of placental ALP (i.e., >0.1 U/L) were analyzed by the simultaneous solution of four equations containing the four unknown ALP isoen.zyme activities. Serum samples that did not contain placental ALP (i.e., samples from the non-pregnant controls and some first-trimester and postpartum samples) were analyzed by the simultaneous solution of three equations (i.e., omitting the value for heat-stable ALP activity) containing the remaining three unknowns. Table 2 gives the CVs for multiple determinations of ALP isoenzyme activities in artificial mixtures, simulating pregnant and non-pregnant sera (i.e., with and without placental ALP).
(c) Sample storage and stability. Consistent with previous studies (see reference 13, pp 301-302, for a review), we found that eight (SD 1.7) months of storage at -20 #{176}C had no effect on ALP activity (Table 3 ). Neither total ALP activity nor any of the isoenzymes measured showed evidence of time-dependent changes in activity during frozen storage (data for hepatic and intestinal ALP activities not shown). Because our method estimates total ALP activity and placental ALP activity directly (i.e., by measurements of total and heat-stable ALP activities), it is not surprising that the variations for repeat measurements of total and placental ALP activities were significantly lower than variations for repeat determinations of bone ALP activity. As a further test for time-dependent changes in ALP activity with storage we also subjected the eight-month repeat isoenzyme Table 4 (i.e., in the legend). Table 5 Table 4 . Both placental and bone ALP activities were significantly increased during pregnancy, and remained increased six weeks postpartum.
(b) Serial samples from four subjects. For each of the four women from whom we obtained a complete series of serum samples during pregnancy, the time-dependent changes in serum ALP activities during pregnancy (data not shown) followed the same pattern as our cross-sectional data.
(c) Effects of metabolic status on serum ALP isoenzyrnes at delivery. The data summarized in Table 6 demonstrate that both total and placental ALP activities at delivery were significantly lower for subjects with ruptured membranes and for subjects in pre-term labor as compared with normal pregnancy, but values for bone ALP were not significantly different.
Discussion
Our results demonstrate that bone ALP activity can be quantified in human serum, even in the presence of placental ALP. Our isoen.zyme assay, adapted from previous methods (14) (15) (16) (17) , recognizes placental ALP activity by its unique stability to inactivation by heat (13), intestinal ALP activity by its sensitivity to inhibition by L-phenylalanine (13, 14, 18) , and bone and hepatic ALP activities by their different sensitivities to heat inactivation (6, 13, 14, 19, 20) .
In characterizing this assay we found that: the CV for repeat determinations of bone ALP activity in four-component, artificial isoenzyme mixtures ranged from 11% to 23% for mixtures containing high and low percentages of bone ALP, respectively. Neither total ALP activity nor any of the Initial applications of this method have revealed that: (a) placental ALP activity in serum is increased during pregnancy (from a value of zero in the non-pregnant woman), then disappears from the circulation; (b) bone ALP activity is also increased during pregnancy, and remains so six weeks postpartum, in non-lactating women; and (c) total and placental, but not bone, ALP activities were lower, at delivery, in women with premature rupture of membranes and those in pre-term labor than in normal-term controls.
The first of these three observations-that placental ALP activityisincreased during pregnancy but is virtually nondetectable six weeks postpartum-is consistent with previous reports of (a) time-dependent changes in total serum ALP activityduring human pregnancy (10) (11) (12) (13) , and (b) a biologicalhalf-life in serum of approximately seven days for the placental isoenzyrne (21) . Similarly, our observations that total and placental ALP activities were lower, at delivery, in subjects with premature rupture of membranes and those in pre-term labor (i.e., compared with normalterm controls)are also consistent with previous data, although our observation of unchanged placental ALP in preeclamptic subjects is not (22, 23) .
Our observations of increased bone ALP activityin serum during pregnancy both confirm and extend a previous report of increased heat-labile (presumably, bone) ALP activity in serum of pregnant women (12) . Previous studies indicate that bone ALP activity can provide a useful index of the rate of bone formation, both in vitro (6) and in vivo (7-9, 14,24) . Thus our data support the hypothesis that maternal bone formation may be increased during pregnancy (5) . Presumably, this increase in maternal bone formation iscompensatory, allowing for replacement of bone lost to resorption when calcium is mobilized in order to meet the fetal demand (2, 3) . Although the mechanisms of calcium mobilization during pregnancy are incompletely understood, our data are also consistent with a previous report (5) that both bone formation and bone resorption are increased in advance of the fetal demand for skeletal calcium (i.e., before the last nine weeks of pregnancy). Because we also found that bone ALP activity remained increased six weeks postpartum, our data further indicate that maternal bone formation may remain increased in non-lactating women after delivery.
